Introduction {#s1}
============

Eukaryotic genomes are pervasively transcribed but the effect of this inter- and intragenic transcription is not fully understood ([@bib16]). Of particular interest is the function of antisense transcription, which alters the chromatin in the vicinity of sense promoters ([@bib13]; [@bib17]; [@bib20]), and is associated with repression, activation or no change in levels of the corresponding sense transcript ([@bib17]). Discerning the mechanism by which antisense transcription functions in gene regulation is confounded by the difficulty in ablating antisense transcription without direct genetic intervention ([@bib1]). A new approach, CRISPR interference (CRISPRi) ([@bib23]), can circumvent these issues by avoiding the need to manipulate endogenous DNA sequences. An endonucleolytically dead version of Cas9 (dCas9) is recruited by single base-pairing guide RNAs (sgRNAs) targeting the non-template (NT) DNA strand, where it blocks transcription strand-specifically at the loci tested ([@bib14]; [@bib23]). In a further adaptation, dCas9 fusion with transcriptional repressors or activators allows both negative and positive regulations of transcription, respectively ([@bib8]; [@bib7]), but the strand-specificity is lost and thus is not suitable for strand-specific repression of antisense transcription. The sgRNA compenent of the CRISPRi system consists of two regions: a constant region (82 nt) that binds to dCas9 and a variable region (20 nt) that is responsible for targeting. The modular nature of the sgRNA lends itself to production from DNA templates constructed using synthetic copper(I)-catalysed alkyne-azide cycloaddition (CuAAC) click chemistry ([@bib4]). The stable artificial triazole DNA linker generated is biocompatibile, being read and accurately copied by DNA and RNA polymerases ([@bib2]; [@bib5]; [@bib6]). We show that click chemistry is an efficient method for sgRNA template construction and that when combined with dCas9, these sgRNAs are as effective as sgRNAs produced from chemically synthesised full-length DNA templates at reducing levels of transcripts in vivo. However, it is still not completely understood how the CRISPRi system functions strand-specifically or why sgRNAs must target the non-template strand.

Here, we use the CRISPRi system to study the effect of blocking antisense transcription at loci with well-characterised sense:antisense transcript pairs. We have previously used a promoter deletion of the antisense transcript *SUT650* at the *HMS2* locus to show that *SUT650* represses *HMS2* sense transcription ([@bib19]). Now we use CRISPRi to examine the effects of blocking *SUT650* antisense transcription to ask (i) whether *SUT650* represses *HMS2* sense transcription *without* a genetic intervention and (ii) whether CRISPRi is strand-specific using, in addition to *HMS2*, an engineered *GAL1* gene with a well-characterised antisense transcript ([@bib18], [@bib17]).

The main conclusion from this study is that CRISPRi at the *HMS2* locus is not fully strand-specific and results in (i) premature termination of the sense transcript and (ii) initiation of a new unstable antisense transcript in the vicinity of the sgRNA binding site. As transcription from this new antisense initiation site extends in to the *HMS2* promoter, there is no net change in *HMS2* sense transcript levels. Thus, CRISPRi redefines the transcriptional landscape at *HMS2*. This suggests that routine use of CRISPRi for gene expression analysis will require rigorous analysis of transcript integrity and function before conclusions can be drawn.

Results and discussion {#s2}
======================

DNA templates for sgRNA production can be made using click chemistry {#s2-1}
--------------------------------------------------------------------

CRISPRi-mediated transcriptional repression requires co-expression of a mature sgRNA and dCas9 ([Figure 1A](#fig1){ref-type="fig"}). A small library of single-stranded DNAs, comprised of templates for sgRNA variable regions, were joined to the constant region using click chemistry ([Figure 1B](#fig1){ref-type="fig"}) and used successfully as templates for PCR, with no significantly different efficiencies when compared to control full-length synthesised oligonucleotides ([Figure 1C](#fig1){ref-type="fig"}). The PCR products were inserted in place of a *URA3* selection cassette in the endogenous *snR52* locus for expression of a transcript that is then processed to form the mature nuclear-retained sgRNA ([Figure 1A](#fig1){ref-type="fig"}). Levels of dCas9 protein were uniform between strains ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Neither insertion of *URA3* into snR52 nor dCas9 expression in the control strains affected growth rate, although strains expressing some sgRNAs grew more slowly indicating a physiological effect ([Figure 1D](#fig1){ref-type="fig"}).

![Experimental strategy for sgRNA template synthesis and incorporation into yeast.\
(**A**) An outline of the experiment. DNA templates for sgRNA production were generated using a click chemistry reaction between a single-stranded DNA oligonucleotide with a 3' alkyne group encoding the constant region (dark blue) and a number of single-stranded DNA oligonucleotides with 5' azido groups encoding the different variable regions (green). The resulting single-stranded DNA oligonucleotide was purified, amplified by PCR and transformed into yeast to replace the *URA3* selection cassette that had previously been introduced into the endogenous *snR52* locus. Correct insertion was confirmed by Sanger sequencing. The expression of the sgRNA is driven from the endogenous RNA polymerase III *snR52* promoter and processed to produce a mature sgRNA. The sgRNA couples with enzymatically dead Cas9 (dCas9, red), expressed under the control of the *TDH3* promoter off a plasmid, to block transcription. See Materials and methods for more detail. (**B**) A polyacrylamide gel visualised by UV shadowing reveals a high efficiency of the click reaction for all the *HMS2* constructs (see [Figure 2E](#fig2){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for positions of the sgRNA binding sites). The sizes of the variable region, DNA splint, constant region and clicked product are indicated. (**C**) PCR efficiencies of the clicked and full-length synthetic DNA oligonucleotides as measured by qPCR with a serial dilution series. N = 3, errors are standard error of the mean (SEM), all differences are not significant p\>0.05. See [Source data 1](#sdata1){ref-type="supplementary-material"}, tab 2. (**D**) Doubling times (min) of the indicated yeast strains grown in complete synthetic media minus leucine. C, strains constructed using clicked oligonucleotides; FLS, strains constructed using full-length synthetic oligonucleotides. N = 10, errors are SEM, \*p\<0.05. See [Source data 1](#sdata1){ref-type="supplementary-material"}, tabs 3--4.](elife-29878-fig1){#fig1}

CRISPRi represses the production of antisense transcripts at *HMS2* and *GAL1* {#s2-2}
------------------------------------------------------------------------------

CRISPRi represses transcription when sgRNAs/dCas9 are targeted to the non-template (NT) strand next to a protospacer adjacent motif (PAM) ([@bib23]) ([Figure 2A](#fig2){ref-type="fig"}). Firstly, we used an engineered version of *GAL1* that has a stable antisense transcript (*GAL1* AS) initiating within an *ADH1* terminator inserted into the *GAL1* coding region ([@bib18]) ([Figure 2B](#fig2){ref-type="fig"}). *GAL1* AS is present in cells grown in glucose-containing media when the *GAL1* gene is repressed and is reduced as cells are switched into galactose-containing media and *GAL1* sense is induced ([Figure 2C](#fig2){ref-type="fig"} lanes 1--3). We designed sgRNAs adjacent to two PAM sequences on the non-template strand near the antisense transcription start site (TSS) (AS+28NT and AS+112NT) and a third strand-specificity control sgRNA on the template strand in this region (AS + 93T) ([Figure 2B](#fig2){ref-type="fig"}). Only sgRNA AS+112NT/dCas9 caused significant (p=0.004) reduction in *GAL1* antisense transcript levels, as assessed by Northern blotting ([Figure 2C,D](#fig2){ref-type="fig"}).

![CRISPRi reduces antisense transcripts at *GAL1* and *HMS2.*\
(**A**) A schematic demonstrating the previously reported requirement of non-template strand targeting by the sgRNA/dCas9 complex for strand-specific transcriptional repression. Arrows indicate the direction of transcription. NT, non-template; T, template; red, dCas9; PAM, protospacer adjacent motif; green/blue, sgRNA. (**B**) A schematic of the engineered *GAL1* locus showing the site of insertion of the *ADH1* terminator (T, red box), the transcription start site for the stable *GAL1* antisense transcript and the positions of the designed sgRNAs (green vertical lines) targeting the non-template (AS+28NT, AS+112NT) and template (AS+93NT) strands with respect to antisense transcription. The position of the Northern blotting probe detecting the *GAL1* AS transcript is shown in purple. (**C**) A Northern blot showing the reduction in *GAL1* antisense transcript (black arrowhead) in the strain expressing sgRNA AS+112NT/dCas9 relative to the no sgRNA control (*GAL1:ADH1*t *snR52::URA3* with dCas9). sgRNAs AS+28NT and AS+93T do not alter *GAL1* AS levels. Samples were taken from cells grown in glucose (t = 0) and at the indicated times after transfer to galactose-containing media (min). Positions of the rRNA are indicated by the short horizontal lines. Ethidium-bromide-stained rRNA is used as loading control. (**D**) Quantification of Northern blotting for the *GAL1* AS transcript at t = 0 in the control no sgRNA strain and the strain with sgRNA AS+112NT. N = 6, errors are SEM, \*p=0.004. See [Source data 1](#sdata1){ref-type="supplementary-material"}, tabs 10--12. (**E**) A map of the *HMS2* locus showing the *HMS2* AS transcript, *SUT650* (black arrow, transcript B) and positions of the three sgRNAs targeting *SUT650* (green vertical lines). The position of the Northern blotting probe to detect *SUT650* (H1 AS) is shown by the purple line. (**F**) A Northern blot probed with *HMS2* antisense probe H1 (see schematic in (**E**)) showing the level of *SUT650* (black arrowhead, transcript B) in the no sgRNA control (*snR52::URA3* with dCas9) strain and strains expressing the indicated antisense-targeting sgRNAs. Deletion of *XRN1* allows detection of a shorter antisense transcript (B^t^) in the strain expressing AS+243NT. Positions of the rRNA are indicated by the short horizontal lines. \*Represents cross-hybridisation with the 25S rRNA. A blot probed for the 18S rRNA is used as loading control. (**G**) Quantification of the level of *SUT650* (transcript B) reduction in the strains expressing each of the three antisense sgRNAs relative to the control no sgRNA strain. N = 4--8, errors represent SEM, \*p\<0.05. Click-linked and full-length synthetic sgRNA AS+243NT templates behave similarly. See [Source data 1](#sdata1){ref-type="supplementary-material"}, tabs 5--9. (**H**) Northern blots with a series of *HMS2* antisense-specific probes. A new shorter antisense transcript (B^t^) can be detected upon *XRN1* deletion in the strains expressing sgRNA AS+243NT/dCas9. Two clones of the CRISPRi strains produced using clicked (**C**) or full-length synthetic (FLS) DNA oligos for strain construction are shown. Positions of the antisense-specific probes (purple) and the site of sgRNA AS+243NT/dCas9 binding (green vertical line) are shown in the schematic. Positions of the rRNA on the Northern blot are indicated by the short horizontal lines. \*Represents cross-hybridisation with the 25S rRNA. Ethidium-bromide-stained rRNA is used as loading control.](elife-29878-fig2){#fig2}

Next, we examined the *HMS2* locus which has a stable antisense transcript, *SUT650*, initiating within the 3' coding region of *HMS2* ([@bib19]; [@bib21]). We designed three *SUT650*-targeting sgRNAs, located 59, 243 and 276 nucleotides downstream of the major *SUT650* TSS on the non-template strand (sgRNAs AS+59NT, AS+243NT, AS+276NT, respectively) ([Figure 2E](#fig2){ref-type="fig"}). Note that there is considerable heterogeneity in the *SUT650* TSS ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and thus in some cells, sgRNA AS+59NT may be binding upstream of the *SUT650* TSS. AS+243NT/dCas9 significantly (p=0.011) reduced *SUT650* ([Figure 2F](#fig2){ref-type="fig"} lanes 1 and 3, 2G) and this repression was comparable for the clicked and control full-length synthetic constructs ([Figure 2G](#fig2){ref-type="fig"}). However, there was no obvious effect of the other two sgRNAs/dCas9 on *SUT650* levels ([Figure 2F](#fig2){ref-type="fig"} lanes 1, 4 and 5, 2G). Consistently, we could only detect dCas9 binding to the site of sgRNA AS+243NT binding and not to the other two *SUT650-*targeting sgRNA binding sites tested ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). CRISPR efficiency has been linked to nucleosome occupancy ([@bib10]; [@bib11]), but we found no correlation between the level of repression and the nucleosome occupancy ([@bib12]) at each of the *SUT650* sgRNA target regions ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). However, other factors such as sequence determinants can also influence repression ([@bib9]). These results at *GAL1* and *HMS2* confirm CRISPRi is suitable for reducing levels of antisense transcripts in yeast but controls are needed for each sgRNA designed to ensure that repression has been achieved.

CRISPRi repression of *SUT650* induces a new shorter antisense transcript at *HMS2* {#s2-3}
-----------------------------------------------------------------------------------

At *HMS2*, sgRNA AS+243NT/dCas9 was able to reduce *SUT650* transcript levels significantly ([Figure 2F,G](#fig2){ref-type="fig"}). Since *SUT650* is a substrate for the major cytoplasmic 5'−3' exonuclease Xrn1 ([Figure 2F](#fig2){ref-type="fig"}, lanes 1 and 2), we investigated whether the CRISPRi-induced *SUT650* reduction was due to direct repression of *SUT650* transcription and/or a reduction in *SUT650* stability. Whilst *SUT650* was not stabilised upon *XRN1* deletion in the strain expressing AS+243NT/dCas9, supporting previous studies that CRISPRi operates via a transcriptional block ([@bib23]) ([Figure 2F](#fig2){ref-type="fig"}, lanes 3 and 6, transcript B), we detected a shorter antisense transcript ([Figure 2F](#fig2){ref-type="fig"}, lane 6, transcript B^t^). To map transcript B^t^, we used a series of Northern blotting probes across the locus ([Figure 2H](#fig2){ref-type="fig"}). With antisense-specific probes H1 and H2 in the *HMS2* gene promoter and 5' coding region, respectively, we could detect antisense transcript B^t^, indicating that it extends into the *HMS2* sense promoter. However, probe H4 at the 3' end of the *HMS2* gene was unable to hybridise to B^t^, indicating that B^t^ initiates upstream of this site. So whilst CRISPRi successfully blocked the original *SUT650*, a new Xrn1-sensitive unstable antisense transcript (B^t^) was created. This is potentially due to changes in the chromatin structure caused by AS+243NT/dCas9 binding to this region ([@bib10]; [@bib11]) or by blocking *SUT650*, creating an environment that is permissive for transcription initiation ([@bib18]). We note that using probe H4 we were also unable to detect *SUT650* initiating from its WT start site but terminating at the AS+243 NT binding site, due to its small size (\~243 nt).

CRISPRi-induced *GAL1* AS repression does not affect the *GAL1* sense transcript {#s2-4}
--------------------------------------------------------------------------------

We tested whether *GAL1* AS repression by AS+112NT/dCas9 affected the *GAL1* sense transcript. Previously we mutated a TATA-like sequence to ablate antisense transcription but observed no difference in *GAL1* sense transcript levels in the population under repressive or activating conditions ([@bib17]). Using CRISPRi, we also observed no significant change in *GAL1* sense transcript levels or size ([Figure 3A,B](#fig3){ref-type="fig"}). Additionally, we observed no leaky expression of the *GAL1* sense transcript under repressive conditions (glucose) when the *GAL1* AS transcript was blocked ([Figure 3A](#fig3){ref-type="fig"}, t = 0). To support a strand-specific transcriptional block of antisense transcription, *GAL1* sense transcript polyA site usage was unaffected by sgRNA AS+112NT/dCas9 ([Figure 3C](#fig3){ref-type="fig"}). Furthermore, *XRN1* deletion in this strain also did not affect polyA site usage, ruling out a partial double-stranded transcriptional block and subsequent destabilisation of the resulting truncated sense transcript ([Figure 3C](#fig3){ref-type="fig"}).

![*HMS2* and *GAL1* sense transcripts are differently affected by blocking of their respective antisense transcripts.\
(**A**) A Northern blot probed for the *GAL1* sense transcript (black arrow) in the control strain with no sgRNA (*GAL1 ADH1*t *snR52::URA3* with dCas9) and in the strain expressing sgRNA AS+112NT/dCas9. Samples were taken from cells grown in glucose (t = 0) and at the indicated times after transfer to galactose-containing media (min). Ethidium-bromide-stained rRNA is used as a loading control. (**B**) Quantification of the Northern blot shown in (**A**) at t = 90. N = 4, error bars represent SEM, change is statistically non-significant (n.s.) p=0.062. See [Source data 1](#sdata1){ref-type="supplementary-material"}, tabs 10--12. (**C**) A schematic showing the results of *GAL1* sense transcript 3' end mapping by RACE in the strains indicated. All distances are shown relative to the sense TSS. Transcript cleavage and polyadenylation occurs beyond the position of the *GAL1* AS-blocking AS+112NT sgRNA shown (green vertical line). (**D**) A Northern blot probed with *HMS2* sense probe H1 (purple) showing the level of *HMS2* sense (black arrowhead, transcript A) in the no sgRNA control (*snR52::URA3* with dCas9) strain and strains expressing the indicated antisense-targeting sgRNAs. A truncated sense transcript (A^t^) was also detected in the strain expressing AS+243NT. C and C' are read-through *HMS2-BAT2* transcripts (see \[[@bib19]\]). Positions of the rRNA are indicated by the short horizontal lines. Ethidium-bromide-stained rRNA is used as loading control. (**E**) Northern blots with a series of *HMS2* sense-specific probes detecting the regions indicated in the schematic. The position of the sgRNA AS+243NT/dCas9 binding site is shown (green vertical line). Positions of the rRNA are indicated by the short horizontal lines. Ethidium-bromide-stained rRNA is used as loading control.](elife-29878-fig3){#fig3}

CRISPRi-induced *SUT650* repression truncates the *HMS2* sense transcript {#s2-5}
-------------------------------------------------------------------------

Previous work shows that reducing *SUT650* transcription increases *HMS2* sense transcript levels ([@bib19]). However, blocking *SUT650* by AS+243NT/dCas9 did not similarly increase *HMS2* sense levels ([Figure 3D](#fig3){ref-type="fig"}, lanes 1 and 3). To our surprise, in addition to the full-length *HMS2* sense transcript (A), we detected a considerably shortened *HMS2* sense transcript (A^t^). Since the combined levels of the truncated and full-length transcripts are similar to those in the strain not expressing an sgRNA, independent of the presence of *XRN1* ([Figure 3D](#fig3){ref-type="fig"}, lanes 1 and 3 or 2 and 6), we hypothesised that the AS+243NT/dCas9 complex bound within the *HMS2* coding region may be causing partial premature sense transcription termination, leading to transcript A^t^. Thus, we mapped the 3' end of *HMS2* S by Northern blotting using a series of strand-specific probes across the locus ([Figure 3E](#fig3){ref-type="fig"}). Both transcripts A and A^t^ could clearly be detected using the probes upstream of the AS+243NT/dCas9 binding site (probes H1, H2, H3), but the truncated transcript was undetectable using probe H4 downstream of this site. Thus, the transcriptional block caused by AS+243NT/dCas9 is not strand-specific and re-defines the transcriptional landscape at the *HMS2* locus by creating a chromatin environment that is suitable for both transcription initiation and termination. To see if we could more directly target and block *HMS2* sense transcripts, we designed three sgRNAs to bind the non-template strand adjacent to PAM sites near the *HMS2* sense TSS (S+77NT, S+106NT, S+179NT) and monitored their effects on both *HMS2* sense and antisense transcripts ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). However, these sgRNAs gave no CRISPRi repression as indicated by the unchanged transcript levels and integrity.

CRISPRi-induced antisense repression at *HMS2* and *GAL1* is not as efficient as previous methods {#s2-6}
-------------------------------------------------------------------------------------------------

We compared the repression efficiency of CRISPRi with our previously used genetic interventions. At *GAL1,* mutation of a TATA-like sequence within the *ADH1* terminator greatly reduced the level of the *GAL1* antisense transcript ([Figure 4A,B](#fig4){ref-type="fig"}) ([@bib17]). Lowered *GAL1* AS transcript levels could result from either reduced transcription or transcript destabilisation (or a combination of the two). To differentiate between these possibilities, we deleted the major cytoplasmic 5'−3' exonuclease *XRN1*. Since *XRN1* deletion in the TATA mutant strain only slightly increased *GAL1* AS levels, this suggests that most repression was at the level of transcription rather than altering transcript stability ([Figure 4B,C](#fig4){ref-type="fig"}). By contrast, *XRN1* deletion in the strain expressing AS+112NT/dCas9 did result in some upregulation of *GAL1* AS ([Figure 4B,C](#fig4){ref-type="fig"}), indicating that antisense transcript repression was not as great in this strain. Unlike at *HMS2* ([Figure 2F,G](#fig2){ref-type="fig"}), this stabilised *GAL1* AS transcript was the same size as in the control and so likely represents stabilisation of the transcripts escaping repression rather than novel transcripts.

![CRISPRi block of *SUT650* and *GAL1* AS is not as efficient as previous genetic interventions.\
(**A**) A schematic showing the previously used genetic intervention to repress the *GAL1* AS transcript ([@bib17]). In the TATA mutant construct, a TATA box within the engineered *ADH1* terminator (T) is scrambled and the level of *GAL1* antisense transcript is reduced. (**B**) A Northern blot probed for the *GAL1* antisense transcript (black arrowhead) comparing the two methods of reducing antisense at this locus in the presence (top blot) or absence (bottom blot) of *XRN1*. All samples were run on the same gel and the blots were exposed to film for the same time. Samples were taken from cells grown in glucose (t = 0) and at the indicated times after transfer to galactose-containing media (min). Positions of the rRNA are indicated by the short horizontal lines. Ethidium-bromide-stained rRNA is used as loading control. (**C**) Quantification of the Northern blot in (**B**) at t = 0. N = 2, errors represent the SEM, \*p=0.026, n.s. non-significant. See [Source data 1](#sdata1){ref-type="supplementary-material"}, tab 12. (**D**) A schematic of the *HMS2-BAT2* locus, showing the *HMS2* sense and antisense transcripts (**A and B**), the *HMS2-BAT2* di-cistronic transcripts (**C and C'**) and the *BAT2* sense transcript (**D**). Cells switch between sense- and antisense-dominant states in which the indicated transcripts are produced ([@bib19]). (**E**) The *HMS2-BAT2* locus and associated transcripts in the wild-type (WT) strain and strains that repress the *SUT650* transcript. In the *HMS2:URA3* strain, the entire coding region of *HMS2* is replaced by that of *URA3*. (**F**) Northern blots comparing the efficiency of *SUT650* reduction by replacement of the *HMS2* coding region with that of *URA3* versus CRISPRi with sgRNA AS+243NT and the relative effects of these two strategies on the *HMS2* sense and *BAT2* transcripts shown in (**E**). The WT (BY4741) and *HMS2.URA3* strains have been transformed with plasmid pRS315 to allow for growth on complete synthetic media lacking leucine and thus comparisons with the CRISPRi strains. Positions of the rRNA are indicated by the short horizontal lines. \*Represents cross-hybridisation with the 25S rRNA. Ethidium-bromide-stained rRNA is used as loading control.](elife-29878-fig4){#fig4}

Next we compared the efficacy of AS+243NT/dCas9 with previous experiments to ablate *SUT650*, where we replaced the entire *HMS2* coding region, including the antisense TSS with the *URA3* coding region (*HMS2:URA3*) ([@bib19]). This successful block of *SUT650* transcription increased levels of the *HMS2* sense transcript, the di-cistronic *HMS2-BAT2* transcript and consequently decreased levels of the downstream gene, *BAT2*, due to transcriptional interference ([Figure 4D--F](#fig4){ref-type="fig"}). Whilst CRISPRi resulted in a similar decrease in *SUT650* as *HMS2:URA3*, neither the *HMS2*, *BAT2* nor *HMS2-BAT2* di-cistronic transcripts were altered ([Figure 4F](#fig4){ref-type="fig"}). The discovery that whilst AS+243NT/dCas9 represses *SUT650*, a new unstable *HMS2* antisense transcript is induced and the sense transcript is prematurely terminated could explain why blocking *SUT650* using CRISPRi and the *URA3* gene body replacement strategies did not give the same results ([Figure 4F](#fig4){ref-type="fig"}). Thus, CRISPRi is not as effective as a genetic mutation in reducing levels of either the *GAL1* or *HMS2* AS transcripts.

Concluding remarks {#s2-7}
------------------

Although CRISPRi has been used to strand-specifically repress antisense transcription at *GAL10* ([@bib14]) and *GAL1* (this work), here we demonstrate that this is not true at *HMS2*. This may reflect the vastly different transcription levels for the galactose-inducible genes (high) compared to *HMS2* (low). Furthermore, a study in human K562 cells found that CRISPRi-induced repression did not correlate with which strand was targeted at 49 genes, although the mechanism behind this observation was not investigated ([@bib7]).

This work extends our previous hypothesis ([@bib19]), allowing us to propose that, rather than acting as a roadblock, the binding of the sgRNA/dCas9 complex at *HMS2* creates a new chromatin environment, either directly or indirectly via the blocking of antisense transcription, which is permissible for transcription initiation and termination. Thus, new transcription units are generated that result in novel sense and antisense transcripts of varying stabilities that are therefore not always detectable. This redefinition of the transcriptional landscape highlights the levels of controls and locus understanding needed before results from using CRISPRi can be interpreted.

Materials and methods {#s3}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation                                                                       Source or reference                                                      Identifiers                                                                       Additional information
  or resource                                                                                                                                                                                                                                                               
  ---------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Gene (*Sacccharomyces*\      *HMS2*                                                                                                                                                     YJR147W; SGD ID\                                                                  
  *cerevisiae*)                                                                                                                                                                           S000003908;\                                                                      
                                                                                                                                                                                          RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093); SGD,\               
                                                                                                                                                                                          RRID:[SCR_004694](https://scicrunch.org/resolver/SCR_004694)                      

  Gene (*S. cerevisiae*)       *GAL1*                                                                                                                                                     YBR020W; SGD ID\                                                                  
                                                                                                                                                                                          S000000224;\                                                                      
                                                                                                                                                                                          RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093); SGD,\               
                                                                                                                                                                                          RRID:[SCR_004694](https://scicrunch.org/resolver/SCR_004694)                      

  Gene (*S. cerevisiae*)       *BAT2*                                                                                                                                                     YJR148W; SGD ID\                                                                  
                                                                                                                                                                                          S000003909\                                                                       
                                                                                                                                                                                          RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093); SGD,\               
                                                                                                                                                                                          RRID:[SCR_004694](https://scicrunch.org/resolver/SCR_004694)                      

  Gene (*S. cerevisiae*)       *snR52*                                                                                                                                                    SGD ID S000006443;\                                                               
                                                                                                                                                                                          RRID:[SCR_003093](https://scicrunch.org/resolver/SCR_003093);\                    
                                                                                                                                                                                          SGD, RRID:[SCR_004694](https://scicrunch.org/resolver/SCR_004694)                 

  Strain, strain background\   see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}            see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}   *Saccharomyces cerevisiae*,\                                                      see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}
  (*S. cerevisiae*)                                                                                                                                                                       NCBITaxon:1247190;\                                                               
                                                                                                                                                                                          SGD, RRID:[SCR_004694](https://scicrunch.org/resolver/SCR_004694)                 

  Genetic reagent\             see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}            see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}   see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}            see [Supplementary file 1C](#supp1){ref-type="supplementary-material"}
  (*S. cerevisiae*)                                                                                                                                                                                                                                                         

  Antibody                     Tubulin (rat monoclonal\                                                          Abcam                                                                    Abcam ab6160\                                                                     (1:3333)
                               YL1/2)                                                                                                                                                     RRID:[AB_305328](https://scicrunch.org/resolver/AB_305328)                        

  Antibody                     Cas9 (rabbit polyclonal)                                                          Diagenode                                                                C15310258\                                                                        (1:5000 Western blot);\
                                                                                                                                                                                          RRID:[AB_2715516](https://scicrunch.org/resolver/AB_2715516)                      5 µl/ChIP

  Recombinant DNA\             see [Supplementary file 1A](#supp1){ref-type="supplementary-material"}            Eurofins Genomics                                                        see [Supplementary file 1A](#supp1){ref-type="supplementary-material"}            see [Supplementary file 1A](#supp1){ref-type="supplementary-material"}
  reagent                                                                                                                                                                                                                                                                   

  Recombinant DNA\             Plasmid with\                                                                     ([@bib23]) Addgene                                                       Addgene \#46920\                                                                  PMID:23849981
  reagent                      p*TDH*-dCas9                                                                                                                                               RRID:[SCR:002037](https://scicrunch.org/resolver/SCR:002037)                      

  Sequence-based\              single-stranded DNA\                                                              This study                                                               see [Supplementary file 1A](#supp1){ref-type="supplementary-material"}            synthesised by\
  reagent                      templates for variable and\                                                                                                                                                                                                                  phosphoramidite oligonucleotide\
                               constant sgRNA regions                                                                                                                                                                                                                       synthesis with 3'-alkyne\
                                                                                                                                                                                                                                                                            or 5'-azido modifications\
                                                                                                                                                                                                                                                                            ([@bib6])

  Sequence-based\              see [Supplementary files 1A,B,D,E,F](#supp1){ref-type="supplementary-material"}   Eurofins Genomics                                                        see [Supplementary files 1A,B,D,E,F](#supp1){ref-type="supplementary-material"}   see [Supplementary files 1A,B,D,E,F](#supp1){ref-type="supplementary-material"}
  reagent                                                                                                                                                                                                                                                                   

  Commercial assay\            QIAquick PCR\                                                                     Qiagen; RRID:[SCR_008539](https://scicrunch.org/resolver/SCR_008539)     Cat\# 28106                                                                       
  or kit                       Purification Kit                                                                                                                                                                                                                             

  Chemical compound,\          SYBR green qPCR\                                                                  Bioline                                                                  Cat\# QT605-20                                                                    
  drug                         master mix                                                                                                                                                                                                                                   

  Software, algorithm          Off-spotter sgRNA\                                                                <https://cm.jefferson.edu/Off-Spotter//>                                                                                                                   
                               algorithm                                                                                                                                                                                                                                    

  Software, algorithm          Rotor-Gene Q\                                                                     <https://www.qiagen.com/us/resources/>                                                                                                                     
                               Series Software                                                                                                                                                                                                                              

  Software, algorithm          Fiji/Image J                                                                      <https://imagej.net/Fiji>                                                ImageJ, RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

sgRNA design {#s3-1}
------------

PAM sequences within 300 bp of the TSS in question were identified and the 20 bp immediately adjacent to these were used to design the variable regions of the sgRNAs. These sequences were run through an off-spotter algorithm (<https://cm.jefferson.edu/Off-Spotter//>) to minimise any off-target effects ([@bib22]). The sequence for the engineered constant region and *SUP4* terminator were taken from ([@bib3]; [@bib15]). The *HMS2* sgRNA templates were synthesised as two DNA oligonucleotides to be joined by click chemistry, with the majority of the constant region on one oligonucleotide that could be used for all reactions. To increase the efficiency of the click reaction, the click linkage was designed between a dCpT dinucleotide within the Cas9 handle region. The sequences for the *HMS2* and *GAL1* sgRNA templates are shown in [Supplementary file 1A](#supp1){ref-type="supplementary-material"}. Full-length sgRNA templates were also synthesised for the *GAL1* sgRNAs and as a control for the *HMS2* click chemistry constructs (Eurofins Genomics, Germany).

Click chemistry {#s3-2}
---------------

Single-stranded DNA oligonucleotides complementary to the constant and variable sgRNA regions were synthesised by standard phosphoramidite oligonucleotide synthesis with 3'-alkyne or 5'-azido modifications respectively ([@bib6]) ([Supplementary file 1A](#supp1){ref-type="supplementary-material"}). The click chemistry reaction was performed with a Cu^1^ catalyst and 24--30 nt splint DNAs ([@bib6]). PCR was performed for second strand synthesis, amplification and incorporation of sequences homologous to the site of insertion in *S. cerevisiae*. PCR efficiencies were obtained using qPCR performed three times on a Corbett 6000 Rotorgene with four serial 10-fold dilutions in triplicate. Analysis was performed using Rotor-Gene Q Series Software (Qiagen, Hilden, Germany).

Strain construction  {#s3-3}
--------------------

dCas9, without fusion to a transcriptional repressor domain, was expressed from a plasmid (\# 46920 Addgene \[[@bib23]\]) under the control of the *TDH3* promoter. The DNA templates for sgRNA production were integrated in place of an exogenous *URA3* cassette immediately downstream of the splice site in the endogenous *snR52* locus using homologous recombination followed by 5-FOA selection. Correct insertion was confirmed by genomic DNA Sanger sequencing. *SNR52* is a Pol III-transcribed C/D box small nucleolar RNA (snoRNA) gene and so does not undergo extensive post-transcriptional processing such as capping and polyadenylation, and transcripts from this locus are retained in the nucleus. Additionally, the locus contains a self-splicing site that produces a mature transcript without additional machinery, allowing precise production of a mature sgRNA without any unwanted extensions. Primer sequences for strain construction are listed in [Supplementary file 1B](#supp1){ref-type="supplementary-material"}.

Yeast growth {#s3-4}
------------

The strains used in this study are listed in [Supplementary file 1C](#supp1){ref-type="supplementary-material"}. Strains were grown to mid-log at 30°C in complete synthetic media lacking leucine (for dCas9 plasmid selection). For experiments studying the *GAL1* locus, yeast were grown to mid-log in rich media (YP 2% D/YP 2% Gal) so that the *GAL1* induction kinetics were similar to what we had observed previously ([@bib18]; [@bib17]). dCas9 expression was unaffected by the temporary absence of plasmid selection ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Yeast growth controls {#s3-5}
---------------------

Assessment of growth in liquid culture (CSM-leucine) was achieved using a Bioscreen spectrophotometer that automatically measures the optical density of cultures at 30°C every 20 min for 24 hr. Doubling times were extracted from the gradient of the curves during logarithmic growth.

Northern blotting {#s3-6}
-----------------

Northern blotting was performed as before ([@bib18]; [@bib19]) using asymmetric PCR or in vitro transcription with T7 RNA polymerase to generate the radioactive strand-specific probes for *GAL1* and *HMS2,* respectively. Primers for these reactions are listed in [Supplementary file 1D](#supp1){ref-type="supplementary-material"}. Northern blots were quantified using Fiji/ImageJ ([@bib24]), and images were acquired using a FLA 7000 phosphorimager (GE Healthcare). Images in the figures are scans of exposures to X-ray film.

Western blotting  {#s3-7}
-----------------

dCas9 expression was confirmed after each experiment using an anti-Cas9 antibody (Diagenode C15310258) at 1:5000 dilution and anti-Tubulin (Abcam ab6160) at 1:3333.

Chromatin immunoprecipitation {#s3-8}
-----------------------------

Yeast cells were fixed with 1% formaldehyde (30 min, 22°C) followed by the addition of glycine to 125 mM for 5 min. Cell pellets were collected by centrifugation (3000 rpm, 5 min) before washing twice with 10 ml cold PBS. Cells were re-suspended in cold FA-150 buffer (10 mM HEPES pH 7.9, 150 mM NaCl, 0.1% SDS, 0.1% sodium deoxycholate, 1% Triton X-100) and broken using 1-ml glass beads on a MagnaLyser (Roche) at (2 × 1 min, 6000 rpm, 4°C). Fixed chromatin was sheared by sonication using a biorupter (Diagenode, 30 min, 30 s on, 30 s off, high setting), cleared by centrifugation (10,000 rpm, 15 min, 4°C) and incubated with 5 µl anti-Cas9 antibody (Diagenode C15310258) and 30 µl protein A-dynabeads pre-blocked with 200 µg/ml yeast tRNA, 200 µg/ml BSA and 200 µg/ml glycogen (15--20 hr, 4°C). Beads and attached chromatin were collected using a magnetic rack and washed with TSE-150 buffer (20 mM Tris-Cl pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100) for 3 min, TSE-500 buffer (20 mM Tris-Cl pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100) for 3 min, LiCl buffer (0.25 M LiCl, 10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% dioxycholate, 1 % NP-40) for 15 min and twice with TE, all at 22°C. After washing, chromatin was eluted from the beads for 30 min at 65°C with elution buffer (0.1 M NaHCO3, 1% SDS). Addition of 350 mM NaCl and incubation for 3 hr at 65°C reversed the cross-links before treatment of samples with RNase A for 1 hr at 37°C and proteinase K overnight at 65°C. DNA was purified using a PCR-purification kit (Qiagen) and eluted in 400 µl 1 mM Tris-Cl pH 8.0. Input DNA was diluted accordingly. Real-time quantitative PCR (qPCR) was carried out using a Corbett 6000 Rotorgene and Sybr green qPCR master mix (Bioline). Data (\[IP - no antibody control\]/input) were expressed as a percentage of the input (relative to sgRNA +276 NT). Real-time qPCR primers are listed in [Supplementary file 1E](#supp1){ref-type="supplementary-material"}.

3' RACE mapping {#s3-9}
---------------

Mapping of the 3' end of the *GAL1* sense transcript was performed as ([@bib19]). Primers are listed in [Supplementary file 1F](#supp1){ref-type="supplementary-material"}.
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###### Numerical data for all graphs (referenced in Figure Legends) Tab 1.

Notes about yeast strain names Tab 2. Data supporting [Figure 1C](#fig1){ref-type="fig"} Tab 3. Data supporting [Figure 1D](#fig1){ref-type="fig"} Tab 4. Analysis of data in Tab 3 for [Figure 1D](#fig1){ref-type="fig"} Tab 5. Quantitation of all Northern blots for CRISPRi of *HMS2* AS transcripts supporting [Figure 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"} Tab 6. Quantitation of all Northern blots for CRISPRi of *HMS2* S transcripts experiments 1 and 2 supporting [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Tab 7. Quantitation of all Northern blots for CRISPRi of *HMS2* S transcripts experiments 3 and 4 supporting [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Tab 8. Data analysis of comparison of CRISPRi versus genetic intervention (*URA3*) for HMS2 supporting [Figure 4D--F](#fig4){ref-type="fig"} Tab 9. *HMS2* sliding probes supporting [Figure 3E](#fig3){ref-type="fig"} and 4F Tab 10. *GAL1* AS CRISPRi data supporting [Figure 3A--B](#fig3){ref-type="fig"} Tab 11. All data for *GAL1* CRISPRi supporting [Figure 2](#fig2){ref-type="fig"}-4 Tab 12. Data analysis of comparison of CRISPRi versus genetic intervention (TATA mutant) for *GAL1* supporting [Figure 4B--C](#fig4){ref-type="fig"} Tab 13. Normalised dCas9 ChIP data at *HMS2* supporting [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. Tab 14. Combined dCas9 ChIP data at *HMS2* for replicates 1--3 supporting [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. Tab 15. Raw Ct data for dCas9 ChIP at *HMS2* replicate one supporting [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. Tab 16. Raw Ct data for dCas9 ChIP at *HMS2* replicate two supporting [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. Tab 17. Raw Ct data for dCas9 ChIP at *HMS2* replicate three supporting [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. All raw data can be found at Mendeley Data: <http://dx.doi.org/10.17632/p2652vcdz8.2>.
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###### Supplementary Tables (referenced in the Materials and methods).

\(A\) Templates for sgRNAs (B) Primers for strain construction (C) *Saccharomyces cerevisiae* strains used in this study (D) Primers for construction of Northern blot probe templates (E) Primers for real-time qPCR at *HMS2* (F) Primers for 3' RACE mapping of the *GAL1* sense transcript.
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Decision letter

Shilatifard

Ali

Reviewing Editor

Northwestern University

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"CRISPRi is not strand-specific and redefines the transcriptional landscape\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by James Manley as the Senior Editor. We have attached the reviewers\' comments for you below.

As you will see, the reviewers find your study of great interest to the community, but have also suggested that the paper is technical in nature and somewhat lacks mechanistic insight. We are willing to consider a revised version of your manuscript addressing the comments/concerns of the reviewers, specifically reviewer 2.

Reviewer \#1:

In recent years, transcriptional interference by antisense RNA transcription has been recognized as a relatively frequent means to regulate mRNA expression. Tools enabling antisense transcription arrest without directly affecting sense transcription are required to study the mechanism mediating this effect. The recently reported CRISPRi system, using a modified, partially defective, Cas9 (dCas9) appeared as ideally suited for this since it has been shown to be able to trigger transcription termination in a site specific and, most importantly, strand specific manner, without altering the genomic sequence.

This short report shows that this strand specificity is actually not true at all loci. In addition, it describes an example in which the binding of the guide RNA actually induces spurious transcription initiation, suggesting that it markedly perturbs the local chromatin environment.

I think that the data are suitably convincing. Note, by the way, that this referee has made the similar (unpublished) observations that the termination by this system was not strand specific at yet another locus.

Although one could argue that the main results presented in this manuscript are negative results, I personally think that they are well worth being published to warn further investigators who would wish to use this system and a short report in *eLife* might seem appropriate for that.

The position of the 5\'-end of SUT650 seems incorrectly assigned. Indeed, if one refers to the TIF-seq data from the original Pelechano paper, the main transcription start site for SUT650 (position 705244 on the Crick strand of chromosome X; this is also consistent with the data from Malabat et al., *eLife*, 2015) would be located about 60 nucleotides DOWNSTREAM of the AS-44NT sgRNA binding site (position 705184). Thus, as the other SUT650 sgRNA targeting sequences, AS-44NT would actually be located within the SUT650 transcribed region, downstream from its TSS and not upstream. It could thus not be considered as a \"control\" sgRNA. Could the authors verify this point and, if this is correct, modify the text, [Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} accordingly? This would in no way modify the conclusions of the manuscript.

Reviewer \#2:

In this paper by Howe et al., the authors assess the potential of CRISPRi for strand-specific transcriptional perturbation in budding yeast. They study two genes in depth -- GAL1 and HMS2 -- and compare the effectiveness of CRISPRi to previous approaches (for example deletion of cis-acting motifs such as the TATA box) in wt and Xrn1 deletion strains. Their primary conclusion is that CRISPRi works well in some cases and not in others and requires careful controls. For example, the authors show that the system does repress antisense transcription, but at one of the two studied loci (HMS2), an additional antisense transcript appears from a new initiation site, and the sense transcript is prematurely terminated. In addition, they present a clever tool based on click chemistry for quickly making gRNA. Although I don\'t find the main conclusion revelatory, I commend the authors for their thoroughness. Certainly, this message is one that bears reporting, although I am not quite convinced this result clears the bar for an *eLife* paper.

1\) The authors show that CRISPRi represses the antisense transcript at a GAL1 model gene. They then check whether this repression has transcriptional effects on GAL1 sense transcription and they conclude there is no difference in galactose. However, previous work has shown that antisense at the GAL locus works mostly under repressive conditions. Have the authors repeated this experiment in glucose or raffinose?

2\) The authors show that CRISPRi repression at the HMS2 locus results in a changed transcriptional landscape. Replacement of the HMS locus by URA does not have the same effect, and they suggest that CRISPRi binding causes these additional transcripts. However, it is unclear whether the new transcripts at HMS2 appear because of removal of the antisense, which in itself could change the chromatin landscape and thus the transcriptional landscape, or whether it arises because of binding of dCas9. The same authors have previously published that removal of the GAL10 ncRNA by genetic methods (point mutations of the transcription factor binding sites) also results in additional transcripts not visible in the wildtype (Murray et al., 2015, supplementary figure S5C). Given these findings, it remains unclear whether the new antisense transcript indeed results from the CRISPRi binding. Moreover, it is noteworthy that additional transcripts are also found in some genetic mutants. Control experiments are therefore required for both methods.

3\) The Xrn1 sensitivity is a confounding factor, and I am not sure that strain should be the gold standard for CRISPRi not working. The whole point is that one can get blocking or perturbation in the absence of genetic manipulation. So, for example one concluding sentence \"CRISPRi is not as effective as a genetic mutation in reducing levels of either the GAL1 or HMS2 AS transcripts\" should end with \"\[...\] in the Xrn1 deletion.\"

4\) In a related point, [Figure 4C](#fig4){ref-type="fig"} is a critical part of the argument. The lower panel needs to have significance calculated between the TATA mutant and AS+112NT, since these bars look pretty similar to this referee. Moreover, the similarity between these measurements suggests that the lower panel in [Figure 4B](#fig4){ref-type="fig"} is not quite a representative image.

5\) Lastly, given that CRISPRi does represses the antisense transcript in both loci tested in the study in a strand-specific manner, the title is a bit misleading.

In summary, despite technical issues, I nevertheless find their argument that CRISPRi can have locus-specific effects to be convincing. However, the manuscript is mostly of a technical nature. Most experiments described are control experiments that should be done anyways when using a new method. The observations that CRISPRi can result in different transcripts is good to know when designing such experiments, but there is no proposed mechanistic insight, nor new biology that is learned from this study.

Reviewer \#3:

In this manuscript Howe and collaborators in the Mellor and Brown labs explore the molecular basis of CRISPRi transcriptional interference in the context of yeast anti-sense transcription. This reviewer agrees with the authors that understanding the basis of CRISPRi in anti-sense transcription (and non-coding RNA transcription in general) is an important area of research because it is extremely difficult to establish direct causality with regard to these particular RNAs using genetic perturbations.

In the first section of their manuscript, Howe et al., describe synthesis of sgRNA constructs using \"click-chemistry\" to couple sgRNA variable regions to the constant region. The author\'s then use knock-in yeast strains generated using these constructs to evaluate the effects of CRISPRi on anti-sense transcription at the GAL1 and HMS2 genes. The authors observe that contrary to behaving as a transcriptional road-block when targeted to the non-template strand, dCas9 CRISPRi complexes result in unpredictable changes in chromatin and transcription, resulting in pre-mature termination of sense transcripts and shifting anti-sense transcription initiation sites. Collectively, these results clearly demonstrate that CRISPRi effects are more complex than previously reported and likely depend on locus-specific chromatin context. These observations have broad implications with respect to design of CRISPRi strategies and argue a strong case for careful characterization of transcript isoforms and promoter/termination sites before and after deploying CRISPRi. However, there are some fundamental issues with controls and some of the conclusions drawn that should be addressed before publication.

1\) The authors observe that only a subset of sgRNAs targeting the non-template strand are capable of mediating repression, however, the reasons for this phenomenon are unclear. A simple explanation is that some sgRNAs are not capable of mediating stable dCAS9 interaction with chromatin. The author\'s should test this by performing Chromatin-Immunoprecipitation (ChIP) for dCas9 in their various sgRNA expressing lines to test if dCas9 chromatin occupancy correlates with repression. In my opinion this is an absolutely essential control for interpreting the authors\' experiments.

2\) This reviewer feels that increasing the sgRNA coverage across the sense/antisense transcripts in question would greatly strengthen the manuscript. In its current state, the authors test only 2 sgRNAs towards the GAL1-AS and SUT650 non-template strands, from which they obtain a single functional repressive sgRNA for each anti-sense transcript. As a strand specificity control they test 3 sgRNAs targeting the sense transcript HMS2 and show that none of these has an effect on sense or anti-sense. However, with a hit rate of \~1 in 2, this reviewer is not convinced by authors\' claim that sgRNAs targeting the sense transcript have no effect on antisense transcription. Perhaps the coverage was simply too low to obtain a functional repressive sgRNA. The authors should perform high-density sgRNA tiling experiments (targeting both template and non-template) for either GAL1-AS or SUT650 (not necessary to do both loci). I feel this experiment will dramatically improve the manuscript and instill clarity into the context requirements for CRISPRi mediated repression.

10.7554/eLife.29878.015

Author response

> Reviewer \#1:
>
> In recent years, transcriptional interference by antisense RNA transcription has been recognized as a relatively frequent means to regulate mRNA expression. Tools enabling antisense transcription arrest without directly affecting sense transcription are required to study the mechanism mediating this effect. The recently reported CRISPRi system, using a modified, partially defective, Cas9 (dCas9) appeared as ideally suited for this since it has been shown to be able to trigger transcription termination in a site specific and, most importantly, strand specific manner, without altering the genomic sequence.
>
> This short report shows that this strand specificity is actually not true at all loci. In addition, it describes an example in which the binding of the guide RNA actually induces spurious transcription initiation, suggesting that it markedly perturbs the local chromatin environment.
>
> I think that the data are suitably convincing. Note, by the way, that this referee has made the similar (unpublished) observations that the termination by this system was not strand specific at yet another locus.
>
> Although one could argue that the main results presented in this manuscript are negative results, I personally think that they are well worth being published to warn further investigators who would wish to use this system and a short report in eLife might seem appropriate for that.

We thank the reviewer for recognising the importance of this work as a warning to other researchers.

> The position of the 5\'-end of SUT650 seems incorrectly assigned. Indeed, if one refers to the TIF-seq data from the original Pelechano paper, the main transcription start site for SUT650 (position 705244 on the Crick strand of chromosome X; this is also consistent with the data from Malabat et al., eLife, 2015) would be located about 60 nucleotides DOWNSTREAM of the AS-44NT sgRNA binding site (position 705184). Thus, as the other SUT650 sgRNA targeting sequences, AS-44NT would actually be located within the SUT650 transcribed region, downstream from its TSS and not upstream. It could thus not be considered as a \"control\" sgRNA. Could the authors verify this point and, if this is correct, modify the text, [Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} accordingly? This would in no way modify the conclusions of the manuscript.

We thank the reviewer for pointing this out and apologise for our oversight. We note that there is a large heterogeneity in the position of the transcription start site for SUT650 and the one we had chosen previously (position 705149, published in Nguyen et al., 2014) is one of the many sites. We have now discussed the transcript heterogeneity in the main body of the text and included a supplementary figure with the Pelechano TIF-seq data to illustrate this ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We have also renamed the HMS2 strains in the text and figures based on the new AS-targeting sgRNA positions relative to the major SUT650 TSS at position 705244 identified by this reviewer.

> Reviewer \#2:
>
> In this paper by Howe et al., the authors assess the potential of CRISPRi for strand-specific transcriptional perturbation in budding yeast. They study two genes in depth -- GAL1 and HMS2 -- and compare the effectiveness of CRISPRi to previous approaches (for example deletion of cis-acting motifs such as the TATA box) in wt and Xrn1 deletion strains. Their primary conclusion is that CRISPRi works well in some cases and not in others and requires careful controls. For example, the authors show that the system does repress antisense transcription, but at one of the two studied loci (HMS2), an additional antisense transcript appears from a new initiation site, and the sense transcript is prematurely terminated. In addition, they present a clever tool based on click chemistry for quickly making gRNA. Although I don\'t find the main conclusion revelatory, I commend the authors for their thoroughness. Certainly, this message is one that bears reporting, although I am not quite convinced this result clears the bar for an eLife paper.

We thank the reviewer for their support of the message we are trying to convey to the community. We feel that *eLife*, with its reputation for thoroughness and research integrity, would be an ideal journal for publishing this work.

> 1\) The authors show that CRISPRi represses the antisense transcript at a GAL1 model gene. They then check whether this repression has transcriptional effects on GAL1 sense transcription and they conclude there is no difference in galactose. However, previous work has shown that antisense at the GAL locus works mostly under repressive conditions. Have the authors repeated this experiment in glucose or raffinose?

As presented in [Figure 3A](#fig3){ref-type="fig"}, we observed no leaky expression of GAL1 sense transcript in glucose (t=0) in the absence of the antisense and the sense induction kinetics are similar to the control. We have included a sentence in the manuscript text to explain this.

> 2\) The authors show that CRISPRi repression at the HMS2 locus results in a changed transcriptional landscape. Replacement of the HMS locus by URA does not have the same effect, and they suggest that CRISPRi binding causes these additional transcripts. However, it is unclear whether the new transcripts at HMS2 appear because of removal of the antisense, which in itself could change the chromatin landscape and thus the transcriptional landscape, or whether it arises because of binding of dCas9. The same authors have previously published that removal of the GAL10 ncRNA by genetic methods (point mutations of the transcription factor binding sites) also results in additional transcripts not visible in the wildtype (Murray et al., 2015, supplementary figure S5C). Given these findings, it remains unclear whether the new antisense transcript indeed results from the CRISPRi binding. Moreover, it is noteworthy that additional transcripts are also found in some genetic mutants. Control experiments are therefore required for both methods.

The point made here by this reviewer is a valid one -- we are unable to infer whether it is the binding of sgRNA/dCas9 or the loss of the antisense that is causing the initiation of the new transcripts. It would be experimentally very difficult to show this and we have now clarified the two possible reasons for new transcripts in the text.

However, the main point is that, independent of what is causing the initiation of the new antisense transcript, in the CRISPRi strain, transcription is occurring in the antisense direction into the HMS2 sense promoter and so no conclusions could be made about the function of SUT650 in sense regulation in this strain. The fear is that some investigators may use the CRISPRi system without the proper controls and the current set of experiments is intended to highlight how important these controls are.

> 3\) The Xrn1 sensitivity is a confounding factor, and I am not sure that strain should be the gold standard for CRISPRi not working. The whole point is that one can get blocking or perturbation in the absence of genetic manipulation. So, for example one concluding sentence \"CRISPRi is not as effective as a genetic mutation in reducing levels of either the GAL1 or HMS2 AS transcripts\" should end with \"... in the Xrn1 deletion.\"

We apologise that we were not clear about the reason for performing the experiments in the XRN1 delete and have now clarified this in the text. We chose to use the deletion of XRN1 to stabilise any transcripts that may be being produced in the CRISPRi strains but then rapidly degraded so that, if the experiment is done in an XRN1^+^ background, the transcript could not be detected. This is important mechanistically because often it is the act of antisense transcription that may cause the effect on neighbouring/overlapping transcription units rather than the antisense transcript itself (e.g. Murray et al., 2015). In [Figure 4B](#fig4){ref-type="fig"}, both the TATA mutant and AS+112NT have undetectable GAL1 AS in the top panel. However, upon XRN1 deletion, a little GAL1 AS is stabilised in the TATA mutant but much more is stabilised in the AS+112NT strain. We interpret this to indicate that there is more leaky but unstable GAL1 AS transcript in the AS+112NT strain than in the TATA mutant strain and thus it is true to say that CRISPRi is not as effective as a genetic mutation in reducing levels of GAL1 AS transcriptionin the presence or absence of XRN1. The same logic can also be applied to the new unstable Xrn1-sensitive HMS2 AS transcripts that appear in the AS+243NT (previously called AS+148NT) strain.

> 4\) In a related point, [Figure 4C](#fig4){ref-type="fig"} is a critical part of the argument. The lower panel needs to have significance calculated between the TATA mutant and AS+112NT, since these bars look pretty similar to this referee. Moreover, the similarity between these measurements suggests that the lower panel in [Figure 4B](#fig4){ref-type="fig"} is not quite a representative image.

We have found it very difficult to quantify blots with very low signal levels so we apologise that the image did not appear to be representative of the accompanying quantification. We have now included a more rigorous background subtraction step for the GAL1 AS Northerns and hope that the reviewer is satisfied with the new [Figure 4C](#fig4){ref-type="fig"}. We have also included significance values here. The same alteration in the quantification of GAL1 AS transcript levels has been repeated for the other GAL1 AS blots and [Figure 2D](#fig2){ref-type="fig"} has therefore been remade accordingly.

> 5\) Lastly, given that CRISPRi does represses the antisense transcript in both loci tested in the study in a strand-specific manner, the title is a bit misleading.

We have shown that CRISPRi only works strand-specifically at GAL1, because at HMS2, both the sense and the antisense transcripts are blocked. However, we agree that the original title perhaps didn't reflect this fully so have now changed it to include the words 'at all loci': 'CRISPRi is not strand-specific at all loci and redefines the transcriptional landscape'.

> In summary, despite technical issues, I nevertheless find their argument that CRISPRi can have locus-specific effects to be convincing. However, the manuscript is mostly of a technical nature. Most experiments described are control experiments that should be done anyways when using a new method. The observations that CRISPRi can result in different transcripts is good to know when designing such experiments, but there is no proposed mechanistic insight, nor new biology that is learned from this study.

We agree that most of the experiments we have done should be performed as controls for any CRISPRi experiments but are aware that, especially if CRISPRi is being used for a large-scale screen, this probably won't be done (and may not be a practical proposition). We wish to publish this work to highlight how important it is that these controls are done or perhaps to suggest that CRIPSRi may not always be a suitable technique if the correct controls cannot be performed.

We have also added mechanistic insight in the new [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, where we have performed a ChIP experiment for Cas9 and show that dCas9 is present at the site of sgRNA binding for the sgRNA that successfully represses HMS2 AS transcript but not at those sgRNAs that do not.

> Reviewer \#3:
>
> In this manuscript Howe and collaborators in the Mellor and Brown labs explore the molecular basis of CRISPRi transcriptional interference in the context of yeast anti-sense transcription. This reviewer agrees with the authors that understanding the basis of CRISPRi in anti-sense transcription (and non-coding RNA transcription in general) is an important area of research because it is extremely difficult to establish direct causality with regard to these particular RNAs using genetic perturbations.
>
> In the first section of their manuscript, Howe et al., describe synthesis of sgRNA constructs using \"click-chemistry\" to couple sgRNA variable regions to the constant region. The author\'s then use knock-in yeast strains generated using these constructs to evaluate the effects of CRISPRi on anti-sense transcription at the GAL1 and HMS2 genes. The authors observe that contrary to behaving as a transcriptional road-block when targeted to the non-template strand, dCas9 CRISPRi complexes result in unpredictable changes in chromatin and transcription, resulting in pre-mature termination of sense transcripts and shifting anti-sense transcription initiation sites. Collectively, these results clearly demonstrate that CRISPRi effects are more complex than previously reported and likely depend on locus-specific chromatin context. These observations have broad implications with respect to design of CRISPRi strategies and argue a strong case for careful characterization of transcript isoforms and promoter/termination sites before and after deploying CRISPRi. However, there are some fundamental issues with controls and some of the conclusions drawn that should be addressed before publication.
>
> 1\) The authors observe that only a subset of sgRNAs targeting the non-template strand are capable of mediating repression, however, the reasons for this phenomenon are unclear. A simple explanation is that some sgRNAs are not capable of mediating stable dCAS9 interaction with chromatin. The author\'s should test this by performing Chromatin-Immunoprecipitation (ChIP) for dCas9 in their various sgRNA expressing lines to test if dCas9 chromatin occupancy correlates with repression. In my opinion this is an absolutely essential control for interpreting the authors\' experiments.

We are not the first to observe that, as for CRISPR, some sgRNAs are not effective for CRISPRi e.g. Lenstra et al., 2015. We do not aim to address the question of why only some sgRNAs are repressive in this paper. However, we have now performed a ChIP experiment for (d)Cas9 (see [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) to show that we can't detect dCas9 binding at the sgRNA sites that gave us no repression but have a strong dCas9 signal at the binding site for sgRNA AS+243NT (previously AS+148NT). Thus we have added mechanistic detail to the phenomenon observed by us and others.

> 2\) This reviewer feels that increasing the sgRNA coverage across the sense/antisense transcripts in question would greatly strengthen the manuscript. In its current state, the authors test only 2 sgRNAs towards the GAL1-AS and SUT650 non-template strands, from which they obtain a single functional repressive sgRNA for each anti-sense transcript. As a strand specificity control they test 3 sgRNAs targeting the sense transcript HMS2 and show that none of these has an effect on sense or anti-sense. However, with a hit rate of \~1 in 2, this reviewer is not convinced by authors\' claim that sgRNAs targeting the sense transcript have no effect on antisense transcription. Perhaps the coverage was simply too low to obtain a functional repressive sgRNA. The authors should perform high-density sgRNA tiling experiments (targeting both template and non-template) for either GAL1-AS or SUT650 (not necessary to do both loci). I feel this experiment will dramatically improve the manuscript and instill clarity into the context requirements for CRISPRi mediated repression.

We do not claim that, if we were to find an sgRNA to block HMS2 sense, that this would not also affect the antisense transcript rather that the 3 sgRNAs we tested against HMS2 sense did not repress either the sense or antisense transcripts. We apologise if this was confused in the text and have clarified this section. We included the (negative) results from the 3 sense-targeting sgRNAs again to reiterate the fact that not all sgRNAs are effective and this is an important control to do. We included the HMS2 AS data from the sense sgRNA strains as a control for the sgRNAs also not working on the template strand.

As stated above, we are not aiming to investigate what makes some sgRNAs cause effective transcript repression and others not. We do not feel that testing more sgRNAs would significantly add to the conclusions of the paper, which were that a) CRIPSRi does not always repress transcription b) CRISPRi is not always strand-specific and c) CRISPRi can induce novel transcripts that would confound any analysis. It is also relevant that the highest CRISPRi activity with unfused dCas9 was observed using PAM sites near the relevant TSSs (Qi et al., 2013) as we have done here. Using PAM sites that are more distant from the TSS is unlikely to add any insight into the conclusions we have made here.
